Charles A. Deignan - Jan 18, 2022 Form 4/A - Amendment Insider Report for Clearside Biomedical, Inc. (CLSD)

Role
Chief Financial Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
CLSD
Transactions as of
Jan 18, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
1/28/2022, 03:51 PM
Date Of Original Report
Jan 20, 2022
Previous filing
Sep 23, 2021
Next filing
Dec 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLSD Common Stock Award $0 +46.3K +14.62% $0.00 363K Jan 18, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLSD Stock Option (Right to Buy) Award $0 +139K $0.00 139K Jan 18, 2022 Common Stock 139K $2.19 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock of the Issuer. The shares underlying the RSU vest in 4 equal annual installments on each of January 18, 2023, January 18, 2024, January 18, 2025 and January 18, 2026, subject to the Reporting Person's continuous service as of each such vesting date.
F2 One-fourth of the shares underlying this option vest on January 18, 2023 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such vesting date.

Remarks:

This amendment to the Reporting Person's Form 4 filed with the Securities and Exchange Commission on January 20, 2022 is being filed to correct the total number of stock options and restricted stock units awarded to the Reporting Person on January 18, 2022. Based on the foregoing, the total number of shares beneficially owned following the reported transactions should have been 353,866 instead of 351,366.